Initially, we demonstrated that in bone and soft tissue sarcoma (BSTS) cell lines trabectedin treatment significantly increased phosphorylated histone H2AX (P-H2AX), the marker of DNA double-strand breaks (p < 0.001, Fig. 1a-c). This evidence concerns the gene H2AX and soft tissue sarcoma.